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Edited by Lukas HuberAbstract Herein, we provide evidence that in chicken smooth
muscle, G-protein stimulation by a Rho-kinase pathway leads
to an increase in myosin light chain phosphorylation. Addition-
ally, G-protein stimulation did not increase MYPT1 phosphory-
lation at Thr695 or Thr850, and CPI-17, was not expressed in
chicken smooth muscle. However, PHI-1 was present in chicken
smooth muscle tissues. Both agonist and GTPcS stimulation re-
sult in an increase in PHI-1 phosphorylation, which is inhibited
by inhibitors to both Rho-kinase (Y-27632) and (PKC)
GF109203x. These data suggest that PHI-1 may act as a
CPI-17 analog in chicken smooth muscle and inhibit myosin
phosphatase activity during G-protein stimulation to produce
Ca2+ sensitization.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The regulation of force in smooth muscle involves the phos-
phorylation of the 20 kDa myosin light chain (MLC20).
MLC20 phosphorylation is determined by the activities of
Ca2+-calmodulin dependent MLCK and MLC phosphatase
[1]. Changes in [Ca2+] and the resulting change in MLCK
activity had been thought to regulate the level of MLC20 phos-
phorylation and force [2]. However, recent evidence has dem-
onstrated that a Ca2+-independent pathway can modulate
MLC20 phosphorylation, as it has been well documented that
both agonist [3] and G-protein [4,5] stimulation lead to a Ca2+
sensitization of the contractile ﬁlaments. Further, Ca2+ sensiti-
zation has been demonstrated at normal resting levels of Ca2+
(100 nM), which suggests that there is Ca2+-independent
MLCK activity that increases MLC20 phosphorylation with
inhibition of MLC phosphatase (reviewed in (31)).
MLC phosphatase is a trimeric protein consisting of a cata-
lytic subunit, a myosin binding or myosin phosphatase target-
ing subunit (MYPT1) and a 20 kDa subunit of unknown
function (reviewed in [6]). Activation of G-proteins has been
shown to result in MYPT1 phosphorylation [7], and Rho-
kinase has been demonstrated to phosphorylate MYPT1 at*Corresponding author. Fax: +1 216 368 5586.
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doi:10.1016/j.febslet.2005.06.059Thr695 in the avian [8,9], or Thr697 in the mammalian se-
quence [10], which results in an inhibition of MLC phospha-
tase activity [8] and a Ca2+ independent increase in MLC20
phosphorylation and force (reviewed in [6,11–14]). Evidence
also suggests another pathway, involving PKC, exists for the
inhibition of MLC phosphatase [15,16]. PKC phosphorylates
CPI-17, which in turn binds to the active site of the catalytic
subunit of MLC phosphatase to inhibit phosphatase activity
[15]. In addition, there is evidence that several proteins includ-
ing Rho-kinase [17], Zip kinase [18] and integrin-linked kinase
[19] can directly phosphorylate MLC20 to produce a Ca
2+ inde-
pendent increase in force.
In avian smooth muscle, agonist stimulation has been shown
to inhibit MLC phosphatase activity [7], and there are studies
that implicate both MYPT1 phosphorylation [7] and other reg-
ulatory pathways [18–20] in the mechanism for agonist in-
duced force enhancement. In this study, we investigated the
mechanisms for G-protein mediated regulation of MLC phos-
phatase activity in chicken smooth muscle to determine the sig-
naling molecules and/or pathways involved in the mechanism
for G-protein mediated force enhancement.2. Material and methods
2.1. Tissue preparation
Thin strips (1500 · 500 · 400 lm) of gizzard and aortic smooth
muscle were dissected from either embryonic day (ED) 16/17 or adult
(hatched) chicken. These small strips of tissue were directly placed into
skinning solution or sample buﬀer and used in subsequent experiments.
2.2. Western blotting
The level of MLC20 phosphorylation was determined as previously
described [20,21]. Brieﬂy, the excised tissue was skinned in relaxing
solution (pCa 9) containing 400 lM b-escin and then transferred to a
tube containing either a pCa 9 solution or a pCa 9 solution with
100 lM GTPcS for 15 min. The tissues were then denatured in 10%
TCA in acetone with 10 mM dithiothreitol and stored at 80 C over-
night. Samples were removed and brought to room temperature for
1 h. After centrifuging for 1 min, the TCA was removed and the tissues
were washed three times in acetone with 10 mM DTT. After the ﬁnal
wash, the tissue was dried and cut into ﬁne pieces. MLC20 was solubi-
lized by vortexing the tissue in 8 M urea, 20 mM Tris, 22 mM glycine,
pH 8.6, 1 mM dithiothreitol and 1 mM phenylmethylsulfonyl ﬂuoride.
The samples were run in the absence of SDS through the use of 19:1
acrylamide:bisacrylamide 10% gels containing 40% v/v glycerol. The
running buﬀer contained 20 mM Tris, 22 mM glycine, 1 mM dithio-
threitol, and 1 mM thioglycolic acid, pH to 8.6. The proteins were
transferred to nitrocellulose membrane and probed for MLC20 using
a monoclonal anti-MLC20 antibody (Sigma). The blot was developed
using alkaline phosphatase substrate buﬀer with NitroBlue Tetrazo-
lium and 5-Bromo-4-choloro-3-indolyl phosphate disodium salt. Theblished by Elsevier B.V. All rights reserved.
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using densitometric analysis (Scion Image). Similar methods were used
to determine the level of PHI-1 phosphorylation, using polyclonal
PHI-1 antisera. Also, in order to determine the eﬀect of inhibition of
the PKC and Rho-kinase pathways, 5 lM GF109203x or 10 lM
Y27632 were added to the GTPcS solutions.
To demonstrate that the intensities of non- and phosphorylated pro-
tein from densitometric analysis of the blots of both MLC20 and PHI-1
were in the linear range of the detection system, we determined phos-
phorylation from the same samples of intact aortic smooth muscle
loaded at our standard as well as both one-half and double our stan-
dard protein loading. As demonstrated for PHI-1 (Fig. 1), there was
no signiﬁcant diﬀerence (P > 0.05) in the phosphorylation of either
PHI-1 or MLC20 (data not shown) determined when protein loading
was varied, demonstrating that the immunoblots are in the linear range
of the detection system. Thus, protein phosphorylation determined
from the ratios of the intensities of the phosphorylated and unphos-
phorylated proteins on the immunoblots are not inﬂuenced by diﬀer-
ences in protein loading.
To determine the level of MYPT1 phosphorylation, embryonic and
adult gizzard and aortic tissues were removed and stimulated as in the
MLC20 phosphorylation assay, using pCa 9, with or without 100 lM
GTPcS. MYPT1 was solubilized by vortexing the samples in SDS sam-
ple buﬀer containing 150 mM Tris, pH 6.8, 6% SDS, 0.3% Bromphenol
Blue, and 30% glycerol. The samples were resolved on 180:1 acrylam-
ide:bisacrylamide 14% SDS–PAGE. The proteins were transferred to
nitrocellulose membrane and probed for either MYPT1 or phosphor-
ylated MYPT1 using a polyclonal anti-MYPT1 antibody (Upstate Bio-
technologies) or two diﬀerent phosphorylation-speciﬁc anti-MYPT1
antibodies speciﬁc for phosphorylation at Thr 695 or at Thr 850 (Up-
state Biotechnologies). Similar methods were used to determine the
level of PHI-1 phosphorylation using polyclonal anti-PHI-1 and a
phosphorylation speciﬁc (Thr57) anti PHI-1 antibodies.
The same samples were used to determine the expression of integrin-
linked kinase (ILK), Zip kinase, CPI-17, Rho A and Rho-kinase.
These proteins were resolved on 180:1 acrylamide:bisacrylamide 14%
SDS–PAGE for ILK and Zip kinase and 29:1 acrylamide:bisacryla-
mide 12% SDS–PAGE for CPI-17, PKC, Rho A and Rho-kinase,
and were then transferred to nitrocellulose membrane and probed with
anti-ILK (Sigma), anti-Zip kinase, anti-CPI-17 antibodies, anti-PKC
(Sigma), anti-Rho A (Upstate Biotechnologies), and anti-Rho-kinase
(Upstate Biotechnologies). Blots were developed with alkaline phos-
phatase or chemo-luminescence (Amersham).
2.3. Protein expression and puriﬁcation
E.coli BL21 transformed with an expression vector encoding un-
tagged, full length PHI-1 DNA (a kind gift from Matsumi Eto) were
used to inoculate 4 L of 2· TY media and grown to OD 600 = 0.4. Pro-
tein expression was induced by the addition of 0.4 mM IPTG and the
bacteria were allowed to grow for an additional 3 h. The bacteria wereFig. 1. Protein phosphorylation determined by densitometric analysis
was in the linear range of the detection system. Tissue lysates were
prepared as described (see Section 2) and Western blotting was
performed, and the visualized proteins were analyzed by densitometry.
In this ﬁgure, protein loading was both decreased by 50% (.5·) and
increased by 100% (2·). The load is given above each lane, and PHI-1
phosphorylation for each level of protein loading is displayed below.
There was no diﬀerence signiﬁcant diﬀerence (P > 0.05) for either PHI-
1 phosphorylation (n = 3) or MLC20 (data not shown), demonstrating
that the intensities of the bands are in the linear range of the detection
system. Thus, changes in protein loading do not inﬂuence the
calculation of protein phosphorylation.then collected by centrifugation and lysed. The resulting supernatant
underwent ammonium sulphate precipitation ﬁrst at 30% then 60%
saturation, each stirred at 4 C for 25 min to collect the precipitate.
As determined by 15% SDS–PAGE, the 30% and 60% ammonium sul-
fate precipitates contained the PHI-1 protein and were dialyzed against
three changes of 4 L of 250 mM NaCl, 10 mM MES, 0.1 mM EDTA,
14 mM 2-mercaptoethanol, pH 6. Following dialysis, the samples were
centrifuged and the precipitates containing PHI-1 were collected.
These were dialyzed two times against 4 L of 10 mM MES, 0.1 mM
EDTA, 14 mM 2-mercaptoethanol to remove any excess salts. The dia-
lyzed protein was dissolved in 6 M urea, 10 mMMES, 0.1 mM EDTA,
0.1 mM PMSF, 2 mM 2-mercaptoethanol and resolved by an SP Se-
pharose ion exchange column developed with 0–500 mM NaCl. The
column fractions were resolved by SDS–PAGE andWestern blots were
used to determine those containing PHI-1. These fractions were dia-
lyzed in 0.01% formic acid, 2 mM 2-mercaptoethanol (4 L total) three
times and then freeze-dried to minimize the sample volume for gel ﬁl-
tration. The lyophilized protein was dissolved in 6 M urea, 0.1 mM
EDTA, 150 mM NaCl, 20 mM phosphate buﬀer, pH 7, and resolved
by Mr using Superdex 75 media. The fractions containing PHI-1 were
then collected, dialyzed as before and lyophilized.3. Solutions
Calcium solutions were prepared using a computer program
designed to give a set of free ion concentrations that are ad-
justed for both temperature and ionic strength [22]. The ionic
strength for all solutions was 200 mM and the experiments
were carried out at a temperature of 22 C in pCa 9.0 solution
containing (in mM): 25 BES, 10 EGTA, 0.02 CaCl2, 7.2
MgCl2, 5.5 ATP, 25 creatine phosphate, 56.5 KMS, pH to
7.0 with 1 M KOH, and creatine kinase was added prior to
the experiments.
Intact tissue was bathed in a standard physiologic saline
solution containing (in mM): NaCl, 140; KCl, 4.7; MgSO4,
1.2; CaCl2, 1.6; NaH2PO4, 1.2; MOPS, 2.0; pH, 7.4; D-glucose,
5.0; and EDTA, 0.2. Tissue was stimulated with the agonist
angiotensin II (AII, 0.1 lM), and PHI-1 phosphorylation
was determined as described above.
3.1. Statistics
All values are given as the means ± S.E.M. of between three
and eight experiments, and signiﬁcance was taken at P < 0.05.4. Results
In the present study, we demonstrate that GTPcS stimula-
tion of skinned chicken smooth muscle increases MLC20 phos-
phorylation (Fig. 2 and Table 1), and this increase in MLC20
phosphorylation was inhibited by Y27632, but not
GF109203x (Fig. 3 and Table 1). These data are in agreement
with our previous report demonstrating that in chicken smooth
muscle GTPcS dependent force enhancement was mediated by
a Rho-kinase, not a PKC dependent mechanism [20].
To determine if the G-protein induced increase in MLC20
phosphorylation is mediated by a Rho-kinase dependent phos-
phorylation of MYPT1, we determined MYPT1 phosphoryla-
tion using phospho-speciﬁc antibodies. These studies
demonstrate that there is a baseline level of MYPT1 phosphor-
ylation at Thr695 and Thr850 that does not change after
GTPcS stimulation (Fig. 4). To conﬁrm that these antibodies
were able to detect phosphorylation at their speciﬁc sites, we
phosphorylated MYPT1 in vitro using Rho-kinase [23], and
Fig. 2. GTPcS treatment leads to an increase in MLC20phosphorylation.
GTPcS was added to chicken smooth muscle tissues skinned with b-
escin to determine the eﬀect of G-protein stimulation on MLC20
phosphorylation. ED 16 and adult aorta (A) and gizzard (G) tissues
were at pCa 9 either in the presence (+) or absence () of 100 lM
GTPcS. The lysates were prepared and Western blotting was
performed, and the visualized proteins were analyzed by densitometry
(n = 5–8).
Table 1
MLC20 phosphorylation in response to GTPcS, Y27632 and
GF109203x








ED16 Gizzard 20 ± 3.7 42 ± 2.9 36 ± 0.4 38 ± 2.0
ED16 Aorta 18 ± 3.6 38 ± 2.5 26 ± 2.7 36 ± 1.8
Adult Gizzard 16 ± 4.1 35 ± 3.6 24 ± 3.6 39 ± 3.6
Adult Aorta 18 ± 2.3 47 ± 1.4 36 ± 2.5 44 ± 1.4
Embryonic and adult aorta and gizzard tissues were skinned with 5 mM
b-escin, and stimulated with pCa 9 alone or pCa 9 with either GTPcS
alone, with GTPcS and Y27632, or with GTPcS and GF109203x. The
samples were then resolved and analyzed as in Fig. 2, with the mean-
s ± S.E.M. (MLC20-Pi (%), n = 5–8). In all tissues, GTPcS stimulation
signiﬁcantly (P < 0.05) increased the level of MLC20 phosphorylation,
and the increase was (P < 0.05) partially inhibited by Y27632, but not
GF109203x.
Fig. 3. A Rho-kinase dependent pathway mediates the GTPcS stimu-
lated increase in MLC20phosphoryaltion. Gizzard tissue was treated
with GTPcS in pCa 9 and stimulated with Y-27632 or GF109203x. The
lysates were prepared and analyzed as in Fig. 1 (n = 3–6).
Fig. 4. Stimulation of G-protein pathways does not aﬀect the level of
MYPT1 phosphorylation. Embryonic and adult gizzard (G) and aortic
(A) tissues were at pCa 9 in the presence (+) or absence () of GTPcS.
The samples were then solubilized with SDS sample buﬀer, resolved by
SDS–PAGE and analyzed using Western blotting with either an anti-
MYPT1 antibody or with an anti-phospho-MYPT1 antibody (n = 4–
5). Control lanes (right) show Western blots of puriﬁed MYPT1 and
MYPT1 after Rho-kinase phosphorylation probed with anti-MYPT1
and either the antiphospho-MYPT1 (Thr850) or MYPT1 (Thr695)
antibody, respectively.
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sepciﬁc antibodies. The results also show that MYPT1 phos-
phorylation is isoform speciﬁc. The expression of MYPT1
isoforms is developmentally regulated (Fig. 4): the aorta ex-
presses the splice-in (M133) MYPT1 isoform throughout
development. However, the gizzard expresses M133 during
its embryonic period and both isoforms (M133 and M130)
shortly after hatching, with the ﬁnal ratio of M133:M130
reaching 30:70 in >D7 tissue. The phospho-speciﬁc antibodies
detected a single phosphorylated band in aortic tissue, which
corresponds to the splice-in (M133) isoform, and similarly in
gizzard smooth muscle a single band is seen at the molecular
weight of the splice-in (M133) MYPT1 isoform in aorta, which
corresponds to the higher Mr band in adult gizzard tissue
(Fig. 4). In our previous reports [20,21,24], we found that the
gizzard expressed exclusively the M130 MYPT1 isoform
shortly after hatching. This diﬀerence in isoform expression
could be due to the increased sensitivity of the polyclonal
MYPT1 antibody used in the present study. Furthermore, a
diﬀerent strain of chicken was used in the present study. Others
[25] have demonstrated variability in the expression of CPI-17
among diﬀerent avian species (chicken vs. pigeon), and thus the
change in the strain of chicken could also account for the dif-
ference in M133/M130 MYPT1 expression between our previ-
ous reports [20,21,24] and the present study.
An alternative mechanism for G-protein induced force
enhancement would be a Rho-kinase or PKC mediated phos-
phorylation of CPI-17 [26]. We could not detect the expression
of CPI-17 at any developmental stage (Fig. 5). However, small
signaling molecules are known to be lost after Triton X-100
permeablilization [16]. But, CPI-17 was detected in b-escin
permeabilized rat aorta (Fig. 5, lane 1), demonstrating that it
is not lost during b-escin permeablization of rat tissue making
it unlikely that it was lost during permeablization of the chicken
smooth muscle. If neither MYPT1 phosphorylation nor CPI-17
phosphorylation participates in a Rho/Rho-kinase mediated
pathway for Ca2+ independent force enhancement, there must
be an alternative signaling molecule and/or pathway.
It has been widely appreciated that another phosphoprotein
phosphatase inhibitor is present in tissues where CPI-17 is low
or absent [25,27]. This protein, PHI-1 is an inhibitor of type-1
protein phosphatases with a high degree of homology to
Fig. 5. The smooth muscle speciﬁc inhibitor protein, CPI-17, is not
present in chicken tissues. Skinned embryonic and adult gizzard and
aortic tissues were solubilized and resolved by SDS–PAGE. They were
then analyzed by Western blotting to determine the presence of CPI-17
with a polyclonal anti-CPI-17 antibody (n = 4). Lane 1 is permeabi-
lized rat aorta, as a positive control.
Fig. 6. GTPcS treatment leads to an increase in PHI-1 phosphorylation.
Gizzard and aortic (data not shown) tissues were at pCa 9 in the
presence (+) or absence () of GTPcS. The samples were then
solubilized with SDS sample buﬀer, resolved by SDS–PAGE and
analyzed using Western blotting with either an anti-PHI1 antibody or
with an anti-phospho-PHI-1 antibody (n = 3).
Table 2
PHI-1 phosphorylation in response to GTPcS, Y27632 and
GF109203x








ED16 Gizzard 16 ± 1.2 25 ± 2.1 19 ± 2.5 13 ± 1.5
ED16 Aorta 14 ± 1.0 23 ± 2.0 17 ± 2.2 15 ± 1.6
Adult Gizzard 19 ± 0.7 24 ± 0.8 19 ± 0.2 19 ± 1.3
Adult Aorta 13 ± 1.3 22 ± 1.7 18 ± 1.8 19 ± 1.1
Skinned embryonic and adult aorta and gizzard samples were treated
with pCa9 and stimulated with either GTPcS alone, with GTPcS and
Y27632, or with GTPcS and GF109203x. The samples were then re-
solved and analyzed (see text for details), means ± S.E.M. (PHI-1-Pi
(%), n = 4–6). In all tissues, GTPcS stimulation signiﬁcantly (P < 0.05)
increased the level of PHI-1 phosphorylation, and the increase was
inhibited (P < 0.05) by both Y27632 and GF109203x.
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chicken aortic and gizzard smooth muscle GTPcS stimulation
increased the level of PHI-1 phosphorylation (Fig. 6); at pCa
9, phosphorylationof PHI-1 atThr57was not detectedwhile fol-
lowing GTPcS stimulation, phosphorylation was apparent.
However, this technique requires the use of two diﬀerent anti-
bodies with diﬀering substrate aﬃnities and only a relative level
of PHI-1 phosphorylation can be determined. Therefore, the
method described by Eto et al. [27] was used to determine the
level of PHI-1 phosphorylation. Using this technique, GTPcS
stimulation of skinned chicken smooth muscle produced an
55–60% increase in di-phosphorylated form (Thr57 + Ser142)
of PHI-1 (Fig. 7 and Table 2) consistent with aGTPcSmediated
increase in PHI-1 phosphorylation (Fig. 6) and a resulting in-
crease in its inhibition of MLC phosphatase [27]. To conﬁrmFig. 7. PHI-1 phosphorylation after G-protein stimulation. Embryonic gizzard
and Y27632, or with GTPcS and GF109203x. The samples were then solubiliz
was identiﬁed on Western blots (n = 4–6). Control lanes show Western blots
with anti-PHI-1 and the antiphospho-PHI-1 (Thr57) antibody, respectively.that the lowest protein band (labeled PHI1-2P in Fig. 7) detected
on the urea/glycerol gels is the diphosphorylated form of PHI-1,
we puriﬁed the PHI-1 and phosphorylated the protein in vitro
using Rho-kinase [23]. Both the native protein and phosphory-
lated PHI-1 were run on an urea/glycerol gel and subsequently
probed using an anti-PHI-1 or anti-phosphospeciﬁc PHI-1
(Thr57) antibody, respectively. PHI-1 was detected as a single
protein band corresponding to the upper band (labeled PHI1
inFig. 7)while the anti-phosphospeciﬁc PHI-1 (Thr57) antibody
detected a single band corresponding with the lowest band (la-
beled PHI1-2 in Fig. 7) on the urea/glycerol gels probed with
the polyclonal PHI-1 antibody, suggesting that the three bands
detected using urea/glycerol gels (Fig. 7) represent un-, mono-
and di-phosphorylated PHI-1, as previously demonstrated by
others [27]. To further delineate the signaling pathway for the
GTPcS induced increase in PHI-1 phosphorylation, we used
Y-27632 andGF109203x. Both Y-27632 andGF109203x inhib-
ited theG-protein inducedphosphorylation of PHI-1 (Fig. 7 and
Table 2).
To demonstrate that the increase in PHI-1 phosphorylation
is part of a physiologically signiﬁcant pathway for agonist in-
duced force enhancement, we determined PHI-1 phosphoryla-
tion at rest and following AII stimulation of intact smooth
muscle using phospho-speciﬁc PHI-1 antibodies (Fig. 8A), as
well as PHI-1 antibodies and urea/glycerol gels (Fig. 8B). At
rest PHI-1 phosphorylation for aorta and gizzard, was
17 ± 3.8% and 17 ± 3.5%, respectively, which increased
(P < 0.05) to 24 ± 3.8% and 24 ± 4.1% following agonist stim-
ulation. Both the resting and agonist stimulated level of PHI-1tissues were stimulated at pCa 9 with either GTPcS alone, with GTPcS
ed, resolved through urea/glycerol gels and the phospho-PHI-1 protein
of puriﬁed PHI-1 and PHI-1 after Rho-kinase phosphorylation probed
Fig. 8. PHI-1 phosphorylation after agonist stimulation. (A) PHI-1
phosphorylation was determined in intact gizzard and aortic (data not
shown) tissues at rest or after AII stimulation. The samples were then
solubilized with SDS sample buﬀer, resolved by SDS–PAGE and
analyzed using Western blotting with either an anti-PHI1 antibody or
with an anti-phospho-PHI-1 antibody (n = 3). (B) PHI-1 phosphory-
lation was determined in intact gizzard (top panel) and aortic (lower
panel) tissues at rest and following AII stimulation. The samples were
solubilized, resolved on urea/glycerol gels and the phospho-PHI-1
protein was identiﬁed on immunoblots (n = 3).
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at pCa 9 ± GTPcS (Table 2), demonstrating that the magni-
tude of the increase in PHI-1 phosphorylation in response to
GTPcS stimulation of permeabilized smooth muscle and ago-
nist stimulation of intact tissue is similar.5. Discussion
In general, G-proteins stimulation has been shown to inhibit
MLC phosphatase activity (reviewed in [6,11,13,14]). Several
investigators have demonstrated that agonist stimulation leads
to a Rho/Rho-kinase mediated phosphorylation of MYPT1
[28,29]. However, others have demonstrated that either a
PKC [16,30,31] or Rho-kinase [32,33] induced phosphorylation
of CPI-17 participates in the mechanism for agonist induced
force enhancement. In addition, a direct phosphorylation of
MLC20 by Zip kinase [18], Rho-kinase [17] or ILK [19] has been
shown to occur. However, if inhibition of MLC phosphatase
activity is a common theme for G-protein mediated force
enhancement, it would be diﬃcult to envision how a direct
MLC20 phosphorylation by these kinases could participate in
a physiologically relevant mechanism for force enhancement.
In contrast to several reports [7,29], but similar to others
[26], we found there is a baseline level of MYPT1 phosphory-
lation at Thr695 that does not change after GTPcS stimulation
(Fig. 4). Recently, Cohen [34] demonstrated that Rho-kinase
phosphorylates MYPT1 at Thr850, which results in a dissoci-ation of the MLC phosphatase complex from myosin, thus
inhibiting MLC phosphatase activity. However in the present
study, MYPT1 phosphorylation at Thr850 did not change
after GTPcS stimulation (Fig. 4). Similar to MYPT1 phos-
phorylation at Thr695, only phosphorylation of the M133
MYPT1 isoform at Thr850 could be detected, which suggests
that MYPT1 phosphorylation by Rho-kinase may be MYPT1
isoform speciﬁc. Nonetheless, these results strongly suggest
that in chicken smooth muscle MYPT1 phosphorylation at
either Thr695 or Thr850 does not participate in the mechanism
for agonist induced force enhancement.
Our results are similar to those reported for rabbit femoral
arterial smooth muscle strips, in which MYPT1 phosphoryla-
tion at Thr641 did not change during histamine or ET-1 stim-
ulation [26]. These investigators showed that although there is
no change in MYPT1 phosphorylation at its inhibitory site,
there is an increase in phosphorylation at Thr799. However,
the results of the present study (Fig. 4) show that phosphory-
lation of the chicken MYPT1 is isoform speciﬁc. Thus, phos-
phorylation may not occur at Thr 641, but rather at Thr 697
of the mammalian MYPT1 sequence. These results could ex-
plain the increase in MYPT1 phosphorylation observed during
G-protein stimulation in experiments using radio-labeled ATP
[7,20] and phosphorylation speciﬁc antibodies in some [28,29]
but not all [26] studies, as increases of MYPT1 phosphoryla-
tion during G-protein stimulation may depend on the relative
expression of the M133/M130 MYPT1 isoforms. Consistent
with this is the demonstration that carbachol stimulation of
rabbit bladder smooth muscle leads to a Rho-kinase dependent
increase in MYPT1 phosphorylation at its inhibitory site
(Thr697) and force enhancement [29]. Similarly, Shin et al.
[35] demonstrated that PDGF2a stimulation of ferret portal
vein led to MYPT1 phosphorylation at Thr695.
An alternative mechanism for agonist induced force
enhancement would be a Rho-kinase or PKC mediated phos-
phorylation of CPI-17. Niiro et al. [26] demonstrated that CPI-
17 phosphorylation increased after agonist stimulation and the
change in Thr38 phosphorylation was inhibited with Y27632.
Similar results have been reported for rabbit vas deferens
and portal vein stimulated with GTPcS [36]. Others [32] have
demonstrated that histamine stimulation of rabbit femoral ar-
tery increased CPI-17 phosphorylation (Thr38) and produced
force enhancement, which was inhibited by 70% with a PKC
inhibitor and partially reversed by Y27632. Phenylephrine
stimulation of this tissue produced a similar degree of force
enhancement, but less of an increase in CPI-17 phosphoryla-
tion, in which inhibitors of PKC and Rho-kinase were equally
eﬀective for inhibition. However, we could not detect the
expression of CPI-17 at any developmental stage (Fig. 5); mak-
ing a strong case that CPI-17 does not participate in the regu-
lation of MLC phosphatase activity in chicken smooth muscle.
Our results are similar to those reported by Kitazawas group
[25] who were also unable to detect CPI-17 in chicken smooth
muscles using either immunoblotting or RT-PCR, but the
polyclonal antisera detected CPI-17 in pigeon tissues, suggest-
ing that the antisera cross-reacts with avian CPI-17. Thus these
data suggest that neither MYPT1 phosphorylation nor CPI-17
phosphorylation participates in a Rho/Rho-kinase mediated
pathway for Ca2+ independent force enhancement.
It has been widely appreciated that another phosphoprotein
phosphatase inhibitor is present in tissues where CPI-17 is low
or absent [25,27]. This protein, PHI-1 is an inhibitor of type-1
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CPI-17 and is ubiquitously expressed in many cell types [27].
Additionally, the inhibitory potency of PHI-1 for MLC phos-
phatase is increased several fold upon phosphorylation [27].
Furthermore, in vitro phosphorylation of recombinant PHI-1
by PKC revealed three forms of the protein, unphosphory-
lated, mono-phosphorylated (predominately at Ser142 [27]),
and di-phosphorylated at Ser142 and Thr57 [27]. The inhibi-
tion of MLC phosphatase activity by PHI-1 is dependent on
its phosphorylation at Thr57 [27]. Both agonist stimulation
of intact smooth muscle strips (Fig. 8) and GTPcS stimulation
of skinned chicken smooth muscle (Figs. 6 and 7 and Table 2)
produced a signiﬁcant increase in PHI-1 phosphorylation, con-
sistent with G-protein stimulation mediating an increase in
PHI-1 inhibitory potency toward MLC phosphatase. Both
Y-27632 and GF109203x inhibited the G-protein induced
phosphorylation of PHI-1 (Fig. 7 and Table 2). It is unclear
why GF109203x decreases GTPcS induced PHI-1 phosphory-
lation (Fig. 7 and Table 2), but not MLC20 phosphorylation
(Fig. 3 and Table 1) in these tissues. Others have demonstrated
that G-protein stimulation activates both PKC and Rho ki-
nase dependent pathways, and activation of both pathways
lead to force enhancement [32]. However, it is not surprising
that GF109203x inhibits the G-protein mediated increase in
PHI-1 phosphorylation as the sequence of PHI-1 surrounding
the inhibitory site, Thr57 (aa 54–59, GKVTVK), is a consensus
sequence for PKC [37] and PHI-1 is known to be a substrate
for PKC [27,37]. However, GF109203x did not attenuate the
G-protein mediated increase in phosphorylation of MLC20
(Fig. 3 and Table 1), implying that the activation of PKC does
not participate in a physiologically relevant pathway for force
enhancement in chicken smooth muscle. On the other hand,
the GTPcS induced increase in both PHI-1 and MLC20 is
inhibited by Y-27632. These results suggest that agonist
induced force enhancement is due to a G-protein mediated
activation of Rho/Rho kinase, which induces PHI-1 phosphor-
ylation leading to inhibition of MLC phosphatase and an
increase in MLC20 phosphorylation.
Our results with PHI-1 phosphorylation are consistent with
recent reports of others [25]. These investigators demonstrated
that in avian smooth muscle GTPcS stimulation leads to a Rho-
kinase dependent Ca2+ sensitization, and that phorbol ester
stimulation of rabbit and pigeon smooth muscle resulted in a
Ca2+ sensitization, while in chicken smooth muscle it produced
a Ca2+ desensitization. Taken together with our results, the
data could suggest that in chicken smooth muscle G-protein
stimulation leads to a Rho-kinase dependent increase in
PHI-I phosphorylation, which in turn binds to the catalytic
subunit of MLC phosphatase to inhibit its activity to produce
an increase in MLC20 phosphorylation and force. Further,
our results are the ﬁrst to demonstrate that PHI-1 phosphory-
lation increases with agonist stimulation of intact smooth
muscle (Fig. 8), consistent for a role of PHI-1 phosphorylation
in a physiologically relevant pathway for inhibition of MLC
phosphatase during agonist induced force enhancement.
Additionally, both integrin-linked kinase (ILK) [19,38] and
Zip-kinase [29]may participate in smoothmuscle force enhance-
ment. Zip kinase is expressed in chicken smooth muscle during
both embryonic and adult stages (data not shown), and has been
demonstrated to phosphorylate MYPT1 [29]. However, we did
not see an increase in MYPT1 phosphorylation, which would
suggest that if Zip kinase participated in the pathway for forceenhancement, it must be directly phosphorylating MLC20 [18].
Similarly, ILK is expressed in both adult and embryonic chicken
smooth muscle (data not shown), consistent with its ubiquitous
expression in all cell types [38]. Muranyi et al. [38] have demon-
strated ILK is associated with the contractile apparatus of
smooth muscle and can phosphorylate both MYPT1 [38] and
MLC20 [39]. Additionally, ILK has been shown to phosphory-
late both CPI-17 and PHI-1 [37,39], which could implicate
ILK in a signaling pathway for force enhancement.
Thus, our results are consistent with a physiologically rele-
vant pathway for agonist induced force enhancement in chicken
smooth muscle resulting from G-protein induced activation
of Rho/Rho-kinase leading to a phosphorylation of PHI-1,
possibly by Rho-kinase, ILK or even another unidentiﬁed ki-
nase. The phosphorylated PHI-1 would then bind to the cata-
lytic subunit of MLC phosphatase to inhibit the MLC
phosphatase activity and produce a Ca2+ independent increase
in MLC20 phosphorylation and force. A Rho/Rho kinase path-
way leading to PHI-1 phosphorylation and an inhibition of
MLC phosphatase could represent a mechanism for increasing
force in smooth muscle as well as non-muscle cell motility.
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